These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 988594)

  • 1. Long acting methadone.
    Choulis NH; Papadopoulos H; Choulis M
    Pharmazie; 1976 Jul; 31(7):466-70. PubMed ID: 988594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long acting methadone formulation. Part 3: Preparation and in vivo evaluation of tablets containing methadone salts and methadone-naloxone combinations.
    Choulis NH; Abellana-Intaphan L
    Pharmazie; 1977; 32(8-9):518-9. PubMed ID: 594119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained release methadone salts and methadone-naloxone mixtures. Part 2: In vitro studies of methadone release.
    Choulis NH; Sandhu BS; Abellana-Intaphan LA
    Pharmazie; 1977 May; 32(5):287-8. PubMed ID: 561410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preparation of nifidipine pulsatile release tablets].
    Zhang Y; Zhang ZR
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Mar; 35(2):261-3. PubMed ID: 15071935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled release of theophylline from inert matrices: effect of channeling material on release rate.
    Ghaly ES; Malavé MI; Rivera WJ; Martí A
    P R Health Sci J; 1993 Dec; 12(4):255-8. PubMed ID: 8140202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting the formulation of sustained release potassium chloride tablets.
    Senel S; Capan Y; Hincal AA
    Pharmazie; 1991 Nov; 46(11):792-5. PubMed ID: 1811230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and evaluation of a novel delayed-onset sustained-release system of propranolol hydrochloride.
    Feng XM; Ren Q; Zhang WZ; Shen HF; Rong ZX; Fang C; Chen HZ
    J Pharm Pharmacol; 2008 Jul; 60(7):817-22. PubMed ID: 18549667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of khaya gum as a directly compressible matrix system for controlled release.
    Odeku OA; Fell JT
    J Pharm Pharmacol; 2004 Nov; 56(11):1365-70. PubMed ID: 15525442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-release compression-coated core tablet containing nifedipine for chronopharmacotherapy.
    Sawada T; Kondo H; Nakashima H; Sako K; Hayashi M
    Int J Pharm; 2004 Aug; 280(1-2):103-11. PubMed ID: 15265551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation of sustained - release lithium carbonate matrix tablets: influence of hydrophilic materials on the release rate and in vitro-in vivo evaluation.
    Emami J; Tavakoli N; Movahedian A
    J Pharm Pharm Sci; 2004 Nov; 7(3):338-44. PubMed ID: 15576014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained release phenylpropanolamine hydrochloride from ATO 888 matrix.
    Perez MA; Ghaly ES; Marti A
    P R Health Sci J; 1993 Dec; 12(4):263-7. PubMed ID: 8140204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies in release behavior of diltiazem HCl from matrix tablets containing (hydroxypropyl)methyl cellulose and xanthan gum.
    Gohel MC; Amin AF; Patel KV; Panchal MK
    Boll Chim Farm; 2002; 141(1):21-8. PubMed ID: 12064053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-amylose sodium carboxymethyl starch matrices for oral, sustained drug-release: formulation aspects and in vitro drug-release evaluation.
    Brouillet F; Bataille B; Cartilier L
    Int J Pharm; 2008 May; 356(1-2):52-60. PubMed ID: 18280069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kinetics of nifedipine release from porous hydrophilic matrices and the pharmacokinetics in man.
    Leucuta SE
    Pharmazie; 1988 Dec; 43(12):845-8. PubMed ID: 3247376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Citric acid monohydrate as a release-modifying agent in melt extruded matrix tablets.
    Schilling SU; Bruce CD; Shah NH; Malick AW; McGinity JW
    Int J Pharm; 2008 Sep; 361(1-2):158-68. PubMed ID: 18582547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen.
    Cao QR; Choi YW; Cui JH; Lee BJ
    J Control Release; 2005 Nov; 108(2-3):351-61. PubMed ID: 16154656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New oral system for timing-release of drugs.
    Conte U; Maggi L; Giunchedi P; La Manna A
    Boll Chim Farm; 1992 May; 131(5):199-204. PubMed ID: 1445686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation.
    Nabais T; Brouillet F; Kyriacos S; Mroueh M; Amores da Silva P; Bataille B; Chebli C; Cartilier L
    Eur J Pharm Biopharm; 2007 Mar; 65(3):371-8. PubMed ID: 17275270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmaceutical and biological availability of commercial preparations of furosemide.
    Stüber W; Mutschler E; Steinbach D
    Arzneimittelforschung; 1982; 32(6):693-7. PubMed ID: 6889429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.